Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Azevedo, Sergio Jobim; Bedke, Jens; Borchiellini, Delphine; Gafanov, Rustem; McDermott, Raymond S.; Melichar, B.; Nguyen, Allison Martin; Nosov, D.; Plimack, Elizabeth R.; Pouliot, Frédéric; Rini, Brian I.; Soulières, D.; Stus, V.; Tamada, Satoshi; Vynnychenko, I.; Waddell, Tom; Wang, S.

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Authors: Sergio Jobim Azevedo
Jens Bedke
Delphine Borchiellini
Rustem Gafanov
Raymond S. McDermott
B. Melichar
Allison Martin Nguyen
D. Nosov
Elizabeth R. Plimack
Frédéric Pouliot
Brian I. Rini
D. Soulières
V. Stus
Satoshi Tamada
I. Vynnychenko
Tom Waddell
S. Wang
Publication date: 1 January 2021
Publisher: R. Jeffrey Karnes, USA Max Kates, USA M. Pilar Laguna, The Netherlands Alastair Lamb, UK Richard S. Lee, USA Seth Lerner, USA Evangelos Liatsikos, Greece Stacy Loeb, USA Yair Lotan, USA Stephan Madersbacher, Austria Luis Martı ́nez-Pin ̃ eiro, Spain Sure

Abstract

The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma